Clinical Trials Saved My Life By Mara Klecker When Barbara Hunter found out her melanoma had returned as Stage IV and was in her liver,…
Navigating Melanoma During the Holidays The holiday season is often portrayed as a time of joy, love, and celebration. However, for melanoma cancer patients, it…
The Clinical Trial Experience: A Patient’s Perspective In 2010, Mary Elizabeth Williams was diagnosed with metastatic melanoma. The following year, she was offered the opportunity to participate…
Celebrate Survivorship – Give Towards Melanoma Research Melanoma knows no boundaries. It’s a disease that affects people of all ages, races, and backgrounds. And it’s a devastating…
Melanoma Cancer and Financial Toxicity While being diagnosed with cancer alone can put a person under tremendous amounts of mental and emotional stress, the additional…
National Family Caregiver Month National Caregiver Month is observed every November to honor and appreciate the selfless individuals who dedicate their lives to caring…
Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Published: Oct 21, 2023 Data published in New…
Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma October 13, 2023 17:30 ET| Source: Bristol Myers Squibb In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant…
That Good Night: Life and Medicine in the Eleventh Hour A growing discipline, palliative care medicine remains underutilized. Studies suggest that patients and providers commonly confuse palliative care with end-of-life…
Notes from the Lab: Novel targets for immune checkpoint inhibitors By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory Survival rates of patients with melanoma have drastically improved in the…
Apr. 19, 2026 KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma
Apr. 10, 2026 FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients